British pharmaceutical giant GSK said on Tuesday that it is buying respiratory drug maker Aiolos Bio in a $1 billion deal. Aiolos Bio is a clinical-stage biopharmaceutical company developing treatments for certain respiratory and inflammatory conditions. The deal includes $1 billion upfront payment and up to $400 million in milestone payments. The acquisition adds Aiolos' AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, to GSK's respiratory pipeline. AIO-001 i
GSK Buys Asthma Drug Developer For Up To $1 4bn channelstv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from channelstv.com Daily Mail and Mail on Sunday newspapers.